Lokelma approved in China for the treatment of adult patients with hyperkalaemia
6 January 2020 07:00 GMT Lokelma approved in China for the treatment of adult patients with hyperkalaemia Patients in China will benefit from Lokelma's rapid reduction of potassium in the blood and the sustained treatment effect AstraZeneca's Lokelma (sodium zirconium cyclosilicate) has been approved in China for the treatment of adult patients with hyperkalaemia (elevated levels of potassium in the blood). The approval by the National Medical Products Administration (NMPA) was based on positive results from the extensive Lokelma clinical trial programme